This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
by Zacks Equity Research
The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.
Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.
by Zacks Equity Research
Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).
Auris (EARS) Expands Pipeline with Intranasal Betahistine
by Zacks Equity Research
Auris (EARS) announced that it has strengthened its pipeline by the addition of AM-125 as the third clinical-stage program, which allowed it to expand into the field of vestibular disorders.
Q4 Earnings Faring Well for Pharma ETFs
by Sweta Killa
Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.
Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More
by Zacks Equity Research
Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.
Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo
The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint
AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales
by Zacks Equity Research
AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.
Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down
by Zacks Equity Research
Merck & Co., Inc. (MRK) reported fourth-quarter 2016 earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 88 cents by a penny.
Q4 Scorecard and Analyst Reports for Eli Lilly, ADP & Aetna
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks and a real-time update on the Q4 earnings season.
Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN
by Zacks Equity Research
How will these two drug stocks, MRK & AMGN, which are both scheduled to report Q4 results on Feb 2, fare this earnings season?
Drug Stocks Rally on Trump Meet with Pharma Bigwigs
by Arpita Dutt
Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.
Biotech Stocks Gain on Latest Trump Drug Price Statements
by Ryan McQueeney
President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.
Eli Lilly (LLY) Misses on Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.
Incyte and Calithera Enter into Deal for Oncology Candidate
by Zacks Equity Research
Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.
Lilly (LLY) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
Eli Lilly (LLY) reported fourth quarter earnings of 95 cents on revenues of $5.76 billion.
Is a Surprise Coming for Eli Lilly (LLY) This Earnings Season?
by Zacks Equity Research
Eli Lilly (LLY) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline
by Arpita Dutt
2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.
Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE
by Zacks Equity Research
Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.
Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?
by Zacks Equity Research
We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.
Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.
Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).
Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
by Zacks Equity Research
We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.